Pediatric SLE-towards a comprehensive management plan

Nature Reviews Rheumatology

Volumn 7, Issue 4, 2011, Pages 225-233

  Brunner, Hermine I ^a   Huggins, Jennifer ^a   Klein Gitelman, Marisa S ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DAPSONE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; PREDNISONE; RITUXIMAB;

B LYMPHOCYTE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE SURVEILLANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HUMAN; INFECTION PREVENTION; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; OVARY DISEASE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PUBERTY; REVIEW; RISK FACTOR; SELF CARE; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL;

ADOLESCENT; CHILD; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERDISCIPLINARY COMMUNICATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 79953669202     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.15     Document Type: Review

References (67)

1. Lo, J. T. et al. Sex differences in pediatric systemic lupus erythematosus: a retrospective analysis of 135 cases. J. Microbiol. Immunol. Infect 32, 173-178 (1999).
2. Hochberg, M. C Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725 (1997).
3. Ferraz, M. B. et al. Evaluation of the 1982 ARA upus criteria data set in pediatric patients. Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology. Clin. Exp. Rheumatol. 12, 83-87 (1994).
4. Tucker, L. B. & Fernandez, M. Clinical differences between juvenile and adult onset patients with systemic lupus erythematosus: results from a multiethnic longitudinal cohort. Arthritis Rheum. 54, S162 (2006).
5. Brunner, H. I., Gladman, D. D., Ibañez, D., Urowitz, M. D. & Silverman, E. D. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 58, 556-562 (2008). (Pubitemid 351294890)
6. Mina, R. & Brunner, H. I. Pediatric lupus\are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum. Dis. Clin. North Am. 36, 53-80 (2010).
7. Cook, C D., Wedgwood, R. J., Craig, J. M., Hartmann, J. R. & Janeway, C A. Systemic lupus erythematosus. Description of 37 cases in children and a discussion of endocrine therapy in 32 of the cases. Pediatrics 26, 570-585 (1960).
8. Tucker, L B. et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 17, 314-322 (2008). (Pubitemid 351655799)
9. Brunner, H. I., Sherrard, T. M. & Klein-Gitelman, M. S. Cost of treatment of childhood-onset systemic lupus erythematosus. Arthritis Rheum. 55, 184-188 (2006).
10. Cervera, R. et al. Lessons from the "Euro-Lupus Cohort". Ann. Med. Interne (Paris) 153, 530-536 (2002).
11. Glidden, R. S., Mantzouranis, E. C & Borel, Y Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin. Immunol. Immunopathol. 29, 196-210 (1983). (Pubitemid 13018217)
12. Gonzalez, B. et al. Changes in the survival of patients with systemic lupus erythematosus in childhood: 30 years experience in Chile. Lupus 14, 918-923 (2005). (Pubitemid 41736376)
13. Hersh, A. O. et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 62, 1152-1159 (2010)
14. Gutiérrez-Suárez, R. et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 54, 2989-2996 (2006). (Pubitemid 44497780)
15. Hurley, R. M., Steinberg, R. H., Patriquin, H. & Drummond, K. N. A vascular necrosis of the femoral head in childhood systemic lupus erythematosus. Can. Med. Assoc. J. 111, 781-784 (1974).
16. Ibanez, D., Gladman, D. D. & Urowitz, M. B. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J. Rheumatol. 32, 824-827 (2005). (Pubitemid 40676490)
17. Nakamura, J. et al. Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum. 62, 609-615 (2010).
18. Powell, C., Chang, C., Naguwa, S. M., Cheema, G. & Gershwin, M. E. Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmun. Rev. 9, 721-743 (2010).
19. Tektonidou, M. G., Malagari, K., Vlachoyiannopoulos, P G., Kelekis, D. A. & Moutsopoulos, H. M. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum. 48, 732-736 (2003). (Pubitemid 36302010)
20. Nakamura, J. et al. Development of new osteonecrosis in systemic lupus erythematosus patients in association with long-term corticosteroid therapy after disease recurrence. Clin. Exp. Rheumatol. 28, 13-18 (2010).
21. Nakamura, J. et al. Spontaneous repair of asymptomatic osteonecrosis associated with corticosteroid therapy in systemic lupus erythematosus: 10-year minimum follow-up with MRI. Lupus 19, 1307-1314 (2010).
22. Brunner, H. I. et al. Health-related quality of life and its relationship to patient disease course in Childhood-onset systemic lupus erythematosus. J. Rheumatol. 36, 1536-1545 (2009).
23. Brunner, H. I., Feldman, B. M., Bombardier, C & Silverman, E. D. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in Childhood-onset systemic lupus erythematosus. Arthritis Rheum. 42, 1354-1360 (1999). (Pubitemid 30265592)
24. Brunner, H. I., Silverman, E. D., Bombardier, C & Feldman, B. M. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in Childhood-onset systemic upus erythematosus. Arthritis Rheum. 49, 335-341 (2003). (Pubitemid 36682400)
25. Brunner, H. I. et al. Minimal clinically important differences of the childhood health assessment questionnaire. J. Rheumatol. 32, 150-161 (2005). (Pubitemid 40103515)
26. Ruperto, N. et al. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of mprovement. Arthritis Rheum. 55, 355-363 (2006). (Pubitemid 43887020)
27. Mina, R. et al. Defining and measuring global flares in juvenile systemic lupus erythematosus. Presented at the 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 2010.
28. Meiorin, S. et al. Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus. Arthritis Rheum. 59, 1112-1119 (2008).
29. Moorthy, L. N. et al. Multicenter validation of a new quality of life measure in pediatric lupus. Arthritis Rheum. 57, 1165-1173 (2007). (Pubitemid 47585462)
30. Ho, A., Barr, S. G., Magder, L. S. & Petri, M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 44, 2350-2357 (2001). (Pubitemid 32977503)
31. Ho, A., Magder, L. S., Barr, S. G. & Petri, M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 44, 2342-2349 (2001). (Pubitemid 32977502)
32. Rovin, B. H., Birmingham, D. J., Nagaraja, H. N., Yu, C Y & Hebert, L. A. Biomarker discovery in human SLE nephritis. Bull. NYU Hosp. Jt Dis. 65, 187-193 (2007). (Pubitemid 351412131)
33. Calano, S. J. et al. Cell-bound complement activation products (CB-CAPs) as a source of upus biomarkers. Adv. Exp. Med. Biol. 586, 381-390 (2006).
34. Manzi, S. et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic upus erythematosus. Arthritis Rheum. 50, 3596-3604 (2004). (Pubitemid 39488685)
35. Hinze, C H. et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal Childhood-onset systemic lupus erythematosus disease activity Arthritis Rheum. 60, 2772-2781 (2009).
36. Suzuki, M. et al. Initial validation of a novel protein biomarker panel for active pediatric upus nephritis. Pediatr. Res. 65, 530-536 (2009).
37. Zhang, X. et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 74, 799-807 (2008).
38. Kazderova, M., Jancova, E., Rysava, R., Merta, M. & Tesar, V Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis. Arch. Med. Res. 39, 115-119 (2008). (Pubitemid 350192016)
39. Chaussabel, D. et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29, 150-164 (2008). (Pubitemid 351952461)
40. Costedoat-Chalumeau, N. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 3284-3290 (2006). (Pubitemid 44622099)
41. Brunner, H. I., Klein-Gitelman, M. S., Ying, J., Tucker, L. B. & Silverman, E. D. Corticosteroid use in Childhood-onset systemic lupus erythematosus-practice patterns at four pediatric rheumatology centers. Clin. Exp. Rheumatol. 27, 155-162 (2009).
42. Schanberg, L. E. et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum. 60, 1496-1507 (2009).
43. Guiducci, C et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937-941 (2010).
44. Touma, Z. et al. Mycophenolate mofetil for nduction treatment of lupus nephritis: a systematic review and metaanalysis. J. Rheumatol. 38, 69-78 (2011).
45. Molino, D. et al. Childhood lupus nephritis (LN): mycophenolate mofetil (MMF) as induction and maintenance therapy. Pediat Nephrol. 25, 1878 (2010).
46. Sundel, R. P, Lisk, L. & Grp, A. Mycophenolate mofetil compared with intravenous cyclophosphamide as induction treatment for pediatric lupus nephritis: a randomized trial. Arthritis Rheum. 58, S632-S633 (2008).
47. Lertdumrongluk, P et al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int. 78, 389-395 (2010).
48. Roland, M. et al. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus 18, 441-447 (2009).
49. Houssiau, F. A. et al. Early response to mmunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from ong-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50, 3934-3940 (2004). (Pubitemid 39643941)
50. Somers, E. C., Marder, W., Christman, G. M., Ognenovski, V. & McCune, W. J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 52, 2761-2767 (2005). (Pubitemid 41369104)
51. Silva, C A. & Brunner, H. I. Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus. Lupus 16, 593-599 (2007). (Pubitemid 47359994)
52. Sanz, I. & Lee, F. E. B cells as therapeutic targets in SLE. Nat Rev. Rheumatol. 6, 326-337 (2010).
53. Marks, S. D. & Tullus, K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr. 99, 967-974 (2010).
54. Merrill, J. T et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic upus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222-233 (2010).
55. Huggins, J. L. & Brunner, H. I. Targeting B cells n the treatment of Childhood-onset systemic upus erythematosus. J. Pediatr. 148, 571-573 (2006). (Pubitemid 43776911)
56. Birmingham, D. J. et al. Relationship between albuminuria and total proteinuria in systemic upus erythematosus nephritis: diagnostic and therapeutic implications. Clin. J. Am. Soc Nephrol. 3, 1028-1033 (2008).
57. Ross, A. C., Taylor, C L., Yaktine, A. L. & Del Valle, H. B. Dietary Reference Intakes for Calcium and Vitamin D (The National Academies Press, Washington, D. C., (2011).
58. Bishop, N. et al. Dual-energy X-ray aborptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD Pediatric Official Positions. J. Clin. Densitom. 11, 29-42 (2008). (Pubitemid 351602186)
59. Ardoin, S. P et al. Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort. Lupus 19, 1315-1325 (2010).
60. Metjian, A. & Lim, W. ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis? Hematology Am. Soc. Hematol. Educ. Program 2009, 247-249 (2009).
61. Millet, A., Decaux, O., Perlat, A., Grosbois, B. & Jego, P Systemic lupus erythematosus and vaccination. Eur. J. Intern. Med. 20, 236-241 (2009).
62. Lu, C C et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 29, 444-450 (2011).
63. Kuramochi, Y et al. Cardiac tamponade due to systemic lupus erythematosus in patient with Prader-Willi syndrome after growth hormone therapy. Lupus 16, 447-449 (2007). (Pubitemid 47122220)
64. Yap, H. K., Loke, K. Y., Murugasu, B. & Lee, B. W. Subclinical activation of lupus nephritis by recombinant human growth hormone. Pediatr. Nephrol. 12, 133-135 (1998). (Pubitemid 28165803)
65. Yazdany, J. et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum. 61, 370-377 (2009).
66. Duvdevany, I., Cohen, M., Minsker-Valtzer, A. & Lorber, M. Psychological correlates of adherence to self-care, disease activity and functioning in persons double-blindith systemic lupus erythematosus. Lupus 20, 14-22 (2011).
67. Koneru, S. et al. Adherence to medications in systemic lupus erythematosus. J. Clin. Rheumatol. 14, 195-201 (2008).